CN103989686A - 一种预防或治疗动脉粥样硬化的药物 - Google Patents
一种预防或治疗动脉粥样硬化的药物 Download PDFInfo
- Publication number
- CN103989686A CN103989686A CN201410200607.4A CN201410200607A CN103989686A CN 103989686 A CN103989686 A CN 103989686A CN 201410200607 A CN201410200607 A CN 201410200607A CN 103989686 A CN103989686 A CN 103989686A
- Authority
- CN
- China
- Prior art keywords
- plaque
- preventing
- medicine
- tripterine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 201000001320 Atherosclerosis Diseases 0.000 title abstract description 11
- 229940079593 drug Drugs 0.000 title description 9
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims abstract description 12
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 230000003143 atherosclerotic effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 5
- 230000014509 gene expression Effects 0.000 abstract description 5
- 230000000879 anti-atherosclerotic effect Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229960005370 atorvastatin Drugs 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 3
- 229960003009 clopidogrel Drugs 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种预防或治疗动脉粥样硬化的药物，含有雷公藤红素和药学上可接受的载体。所述药物价格低廉、毒副作用相对较小、适用于各种剂型、具有明显的抗动脉粥样硬化作用，能降低血LDL水平、降低斑块内VEGF的表达。
Description
技术领域
本发明涉及一种药物，具体涉及一种预防或治疗动脉粥样硬化的药物。
背景技术
脑血管病致死和致残率高，幸存者又容易再发，目前脑血管病发病率和死亡率正呈快速地上升，随着人口的老龄化，卒中问题将日益严重，如果不采取及时有效的干预措施，将会给社会和经济带来沉重的负担。随着经济水平的快速发展及人们生活方式的改变，以动脉粥样硬化(Atherosclerosis,AS)为基础的缺血性脑卒中发病率正在快速增长，其中颈动脉粥样硬化斑块与缺血性卒中发生、再发有着密切的关系。随着近年来对AS的研究深入，越来越多的证据表明，大多数引起缺血性事件的病变不是位于血管的最狭窄处，而是因为动脉粥样斑块破裂或裂隙伴随血栓形成造成的血管堵塞所致。因此，动脉粥样硬化的生物学特征——斑块易损性的研究，引起广泛的关注。深入研究颈动脉易损斑块的发生机制、诊断技术和防治措施，对延缓、遏制我国脑血管病发病率和死亡率有着重要的意义。
现代西医中针对易损斑块治疗的药物主要有他汀类药物、抗血小板药物(氯吡格雷)。他汀稳定易损斑块的作用主要是通过降低LDL-C、提高HDL-C、降低甘油三酯，并通过降低斑块氧化脂蛋白水平等途径来稳定易损斑块；氯吡格雷主要通过抑制血小板的活化，抑制血小板作为“炎症细胞”而释放的一些炎症介质，从而达到抑制斑块的进展、抑制斑块破裂继发血栓形成来稳定斑块。这两种药物在稳定斑块方面的作用虽然得到了世界性公认，但这两类药物各自作用靶点有限，且存在的副作用也不能忽视。他汀类药物主要副作用有肝功能受损、横纹肌溶解等；氯吡格雷主要的副作用有全身各处出血，严重时可能出现颅内大出血、消化道大出血危及生命。并且由于这两类药物价格较贵，对于我国来说百姓来说经济负担较重，所以研究作用于多环节、多靶点的全面充分、持久稳定和价格低廉的药物迫在眉睫。我国传统中药药性温和、安全稳定、价格低廉，从中药方面研究稳定斑块药物对于我国来说势必是一条新的道路。
发明内容
本发明的目的在于，解决上述现有技术的不足，提供一种能用于预防或治疗动脉粥样硬化的药物。
为实现上述目的，本发明采用以下技术方案：
一种预防或治疗动脉粥样硬化的药物，含有雷公藤红素和药学上可接受的载体。
本发明的另一个目的是，将雷公藤红素用于制备预防或治疗动脉粥样硬化的药物。
本发明所述雷公藤红素(Tripterine)又名南蛇滕素(Celastrol)，是从雷公藤中提取的三萜类单体成分。
本发明的优点是：本发明所述药物价格低廉、毒副作用相对较小、适用于各种剂型、具有明显的抗动脉粥样硬化作用，能降低血LDL水平、降低斑块内VEGF的表达。
具体实施方式
实施例1：雷公藤红素处理组给予雷公藤红素(以高浓度溶于DMSO中)1mg/kg/d灌胃，即该组动物每天所使用的药物中，雷公藤红素提纯物的含量为1mg/kg，该提纯物的纯度在98％以上。
1.建立兔颈动脉粥样硬化斑块模型实验动物：雄性日本大耳白兔40只，体重2.3-3.0kg，4个月龄，随机分为假手术组(n＝10)、模型组(n＝10)、雷公藤红素处理组(1mg/kg/d、n＝10)、阿托伐他汀处理组(2.5mg/kg/d、n＝10)。方法：所用动物均给予高脂饲料喂养(2％胆固醇+6％花生+92％普通颗粒饲料加工配制)1周后实施颈动脉内膜气体干燥术，术后继续高脂饲料喂养，假手术组除不进行气流内皮干燥外，其余步骤均与其它两组相同。模型制作：实验动物术前12h禁食，不禁水。在严格无菌条件下，动物经速眠新注射液(0.2ml/kg)肌肉麻醉，颈部脱毛清洁消毒后，作颈正中切皮，于甲状软骨上方水平分离右侧颈总动脉，长约2.5cm(如发现颈动脉小分支，则予以单线结扎)，两端以动脉夹阻断血流，4.5号头皮尽可能平行于血管纵轴方向穿刺进入阻断血管的两端，生理盐水冲起置换出官腔内的血液后，接上已调节好流量为250ml/min的气流，历时5min，造成内皮干燥，然后官腔内重新充满生理盐水，放开临时动脉夹恢复血流。湿润棉片轻轻压迫穿刺点3-5min止血。庆大霉素滴于手术野中，缝合皮肤创口并包扎。术后肌注庆大霉素预防感染。于术后雷公藤红素处理组给予雷公藤红素(以高浓度溶于DMSO中)1mg/kg/d灌胃；阿托伐他汀处理组给予阿托伐他汀2.5mg/kg/d灌胃；对照组给予相当剂量的DMSO灌胃。于术后第12周处死所有动物。所有动物均单笼喂饲，饮水不限，自由摄食，每只每天进食120g饲料。2.检测方法：斑块病理学检查：①大体形态观察：动物固定后取出颈动脉全长，肉眼观察，然后纵行剖开，生理盐水洗干净后，观察斑块破裂和血栓形成情况，测量血栓全长和横截面积。②组织病理学检查：切取颈动脉，4％甲醛固定24h后行常规石蜡切片，切片厚度5um，进行HE染色，在光镜下观察血管壁AS病变的组织学形态。应用图像处理软件作形态学分析，测量动脉壁横切面积、粥样斑块面积，计算粥样斑块面积与动脉壁横切面积之比；应用镜下测微尺测量病变部位斑块的脂质池大小、纤维帽厚度、浸润的炎性细胞多少；每个样本测量3次，取平均值。③血液标记物检测：各实验动物到达设计时间点后于清晨空腹取血。检测血脂、血糖。④ELISA法检测炎症因子：按照说明书步骤ELISA法检测血清中MMP-9、CRP的表达。⑤免疫组织化学检测：检测斑块内VEGF。各组间两两比较采用方差分析后的LSD法。
结果：四组动物在初始甘油三酯、总胆固醇、高密度脂蛋白胆固醇(high densithlipoprotein cholesterol，HDL-C)、低密度脂蛋白胆固醇(low densithlipoprotein cholesterol，LDL-C)、CRP、MMP-9等的差别均无统计学意义。与假手术组相比，模型组有较典型的动脉粥样硬化病变，其血甘油三酯、总胆固醇、HDL-C、LDL-C水平上均高于假手术组。与模型组相比，雷公藤红素能干预兔颈动脉斑块的形成(比较斑块面积与颈动脉横截面积的比值，P<0.001)，并与阿托伐他汀组相比差异无统计学意义(P＝0.109)。同时，与模型组相比，雷公藤红素也降低血清LDL水平(P＝0.014)，并与阿托伐他汀组相比差异亦无统计学意义(P＝0.578)。另外，与模型组相比，雷公藤红素显著减少斑块内VEGF的表达(P＝0.013)，而阿托伐他汀组的斑块内VEGF的表达与模型组相比差异无统计学意义(P＝0.554)。
Claims (2)
1.一种预防或治疗动脉粥样硬化的药物，含有雷公藤红素和药学上可接受的载体。
2.雷公藤红素用于制备预防或治疗动脉粥样硬化的药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200607.4A CN103989686A (zh) | 2014-05-13 | 2014-05-13 | 一种预防或治疗动脉粥样硬化的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410200607.4A CN103989686A (zh) | 2014-05-13 | 2014-05-13 | 一种预防或治疗动脉粥样硬化的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103989686A true CN103989686A (zh) | 2014-08-20 |
Family
ID=51304192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410200607.4A Pending CN103989686A (zh) | 2014-05-13 | 2014-05-13 | 一种预防或治疗动脉粥样硬化的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989686A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727599A (zh) * | 2016-12-13 | 2017-05-31 | 张登海 | 一种淋巴细胞抗原96蛋白活化的阻断剂及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101311187A (zh) * | 2007-05-24 | 2008-11-26 | 烟台靶点药物研究有限公司 | 一种雷公藤红素衍生物及其制备方法与用途 |
| CN103059094A (zh) * | 2013-01-24 | 2013-04-24 | 湖北民族学院 | 一种提取雷公藤红素的方法 |
-
2014
- 2014-05-13 CN CN201410200607.4A patent/CN103989686A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101311187A (zh) * | 2007-05-24 | 2008-11-26 | 烟台靶点药物研究有限公司 | 一种雷公藤红素衍生物及其制备方法与用途 |
| CN103059094A (zh) * | 2013-01-24 | 2013-04-24 | 湖北民族学院 | 一种提取雷公藤红素的方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727599A (zh) * | 2016-12-13 | 2017-05-31 | 张登海 | 一种淋巴细胞抗原96蛋白活化的阻断剂及其用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ge et al. | Zinc attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury by activating Nrf2/GPX4 defense pathway | |
| Chen et al. | Activation of autophagy is required for Oroxylin A to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation | |
| Stupnisek et al. | Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin | |
| Jiang et al. | Proanthocyanidin prevents lipopolysaccharide-induced depressive-like behavior in mice via neuroinflammatory pathway | |
| Raffetin et al. | Use of artesunate in non-malarial indications | |
| Lyu et al. | Atractylodin ameliorates lipopolysaccharide and d-galactosamine-induced acute liver failure via the suppression of inflammation and oxidative stress | |
| Ahn et al. | Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells | |
| Ateufack et al. | Gastroprotective and ulcer healing effects of piptadeniastrum Africanum on experimentally induced gastric ulcers in rats | |
| El-Bakry et al. | Therapeutic dose of green tea extract provokes liver damage and exacerbates paracetamol-induced hepatotoxicity in rats through oxidative stress and caspase 3-dependent apoptosis | |
| Huang et al. | Myricetin possesses anthelmintic activity and attenuates hepatic fibrosis via modulating TGFβ1 and Akt signaling and shifting Th1/Th2 balance in Schistosoma japonicum-infected mice | |
| Celestino et al. | Differential redox state contributes to sex disparities in the response to influenza virus infection in male and female mice | |
| CN101721534B (zh) | 鱼腥草总多糖及其制备方法和在制药中的用途 | |
| AU2016207117B2 (en) | The use of diphenol in preparation of medicines for prevention and treatment of cerebral ischemia | |
| US20170065549A1 (en) | Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition | |
| Magalhães et al. | A Betulinic acid derivative, ba5, induces g0/g1 cell arrest, apoptosis like-death, and morphological alterations in Leishmania sp | |
| El Mahdy et al. | Potential protective effects of sildenafil and moringa on experimentally-induced gastric ulcer in rats | |
| CN103989686A (zh) | 一种预防或治疗动脉粥样硬化的药物 | |
| TW201540297A (zh) | 蛇床子素用於製備治療局部腎絲球硬化症之組合物的用途 | |
| CN103393680A (zh) | 小檗碱在治疗非酒精性脂肪肝病药物中的应用 | |
| EP3955947A1 (en) | Method and composition for reversing and/or inhibiting atherosclerosis | |
| Wang et al. | Effect of Huangdisan grain on improving cognitive impairment in VD rats and its mechanism in immune inflammatory response | |
| TW201438710A (zh) | 檸檬醛用於製備治療局部腎絲球硬化症之藥物的用途 | |
| Malvestio et al. | Role of dystrophin in acute Trypanosoma cruzi infection | |
| US20150328272A1 (en) | Compositions for Improving the Development of Arteriosclerotic Vascular Diseases | |
| WO2014063312A1 (zh) | 丹酚酸a预防和\或治疗脑微血管血栓栓塞性疾病的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140820 |